Abstract: The present invention includes composition, methods and kits for detecting and treating brain injury associated fatigue or altered cognition (BIAFAC) in a human patient comprising: identifying a human patient in need of treatment for brain injury associated fatigue or altered cognition associated with an altered intestinal flora; and providing the human patient with a composition comprising at least one of: a Prevotella spp or a Bacteroidies spp bacteria, or one or more agents that increase the amount of the Prevotella spp or the Bacteroidies spp bacteria in an intestinal flora of the human patient to reduce or eliminate the brain injury associated fatigue or altered cognition.

Abstract: The present invention includes composition, methods and kits for detecting and treating brain injury associated fatigue or altered cognition (BIAFAC) in a human patient comprising: identifying a human patient in need of treatment for brain injury associated fatigue or altered cognition associated with an altered intestinal flora; and providing the human patient with a composition comprising at least one of: a Prevotella spp or a Bacteroidies spp bacteria, or one or more agents that increase the amount of the Prevotella spp or the Bacteroidies spp bacteria in an intestinal flora of the human patient to reduce or eliminate the brain injury associated fatigue or altered cognition.

Abstract: Provided herein are isolated CD133+ cells, such as human CD133+ cells, that have been expanded in culture and populations of isolated CD133+ cells that have been expanded in culture. The cells express transcription factors, growth factors, or a combination thereof, at altered levels compared to a naturally occurring CD133+ cell. Also provided are methods, including methods for expanding CD133+ cells and methods for using CD133+ cells.

Abstract: The present invention includes composition, methods and kits for detecting and treating brain injury associated fatigue or altered cognition (BIAFAC) in a human patient comprising: identifying a human patient in need of treatment for brain injury associated fatigue or altered cognition associated with an altered intestinal flora; and providing the human patient with a composition comprising at least one of: a Prevotella spp or a Bacteroidies spp bacteria, or one or more agents that increase the amount of the Prevotella spp or the Bacteroidies spp bacteria in an intestinal flora of the human patient to reduce or eliminate the brain injury associated fatigue or altered cognition.

Abstract: Provided herein are isolated CD133+ cells, such as human CD133+ cells, that have been expanded in culture and populations of isolated CD133+ cells that have been expanded in culture. The cells express transcription factors, growth factors, or a combination thereof, at altered levels compared to a naturally occurring CD133+ cell. Also provided are methods, including methods for expanding CD133+ cells and methods for using CD133+ cells.

Abstract: The present invention concerns the use of transdifferentiated cells to treat pancreatic diseases. More particularly, it provides methods for the culture and transdifferentiation of human cord blood, cells into insulin-secreting cells. It also concerns the endocrine hormones, such as insulin, produced by such cultures, and the use of the transdifferentiated cells in the treatment of diabetes.

Abstract: The present inventions relate to the use of thiazolidinedione compounds, including troglitazone, either alone or in combination with other cancer treatments, for the treatment of cancer. These combination therapies employ thiazolidinedione compounds in conjunction with anticancer treatments, such as chemotherapeutic agents.

Abstract: The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR&ggr;). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPAR&ggr; resulting in loss of cell viability.

Abstract: The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR&ggr;). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further, enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPAR&ggr;, resulting in loss of cell viability.

Abstract: The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR.gamma.). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further, enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPAR.gamma., resulting in loss of cell viability.